ReviewMolecular oncology2015
T-cell receptor gene therapy--ready to go viral?
Review in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.Molecular therapy. Methods & clinical development · 2023Article
- CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2021Review
- Immunostimulatory biomaterials to boost tumor immunogenicity.Biomaterials science · 2020Review
- Gene editing and CRISPR in the clinic: current and future perspectives.Bioscience reports · 2020Review
- Article
- Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine.Frontiers in oncology · 2020Review
- Targeting cancers through TCR-peptide/MHC interactions.Journal of hematology & oncology · 2019Review
- Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.Molecular therapy. Methods & clinical development · 2019Review
- Safety and Tolerability of Adoptive Cell Therapy in Cancer.Drug safety · 2019Review
- A rare population of tumor antigen-specific CD4Journal for immunotherapy of cancer · 2019Article
- Acquired resistance to cancer immunotherapy.Seminars in immunopathology · 2019Review
- Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Current treatment options of T cell-associated immunotherapy in multiple myeloma.Clinical and experimental medicine · 2017Review
- Review
- Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.Oncoimmunology · 2016Article
- Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Molecular oncology · 2015Review
- T-cell receptor gene therapy--ready to go viral?Molecular oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T lymphocytes can be redirected to recognize a tumor target and harnessed to combat cancer by genetic introduction of T-cell receptors of a defined specificity. This approach has recently mediated encouraging clinical responses in patients with cancers previously regarded as incurable. However, despite the great promise, T-cell receptor gene therapy still faces a multitude of obstacles. Identification of epitopes that enable effective targeting of all the cells in a heterogeneous tumor while sparing normal tissues remains perhaps the most demanding challenge. Experience from clinical trials has revealed the dangers associated with T-cell receptor gene therapy and highlighted the need for reliable preclinical methods to identify potentially hazardous recognition of both intended and unintended epitopes in healthy tissues. Procedures for manufacturing large and highly potent T-cell populations can be optimized to enhance their antitumor efficacy. Here, we review the current knowledge gained from preclinical models and clinical trials using adoptive transfer of T-cell receptor-engineered T lymphocytes, discuss the major challenges involved and highlight potential strategies to increase the safety and efficacy to make T-cell receptor gene therapy a standard-of-care for large patient groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.